Experimental Injection Destroys Fat Cells in Early Trials

An experimental injection called CBL-514 is drawing attention after early trial data showed it can trigger fat cells to self destruct, according to a ScienceDaily report on findings presented at the European Association for the Study of Diabetes meeting in Milan. Rather than shrinking fat already stored in cells, the drug pushes adipocytes into apoptosis while reportedly sparing other cell types.

In pooled analysis of two phase 2 trials, participants with a BMI between 22 and 30 received injections every three weeks for up to 12 weeks. At eight weeks, 69.6 percent of treated participants had lost at least 150 mL of subcutaneous fat volume, compared with none in the placebo group. MRI data also showed reductions in visceral fat, the metabolically active tissue surrounding internal organs that is linked to insulin resistance and cardiometabolic risk.

A more speculative finding comes from animal studies, where combining CBL-514 with tirzepatide produced greater weight loss than tirzepatide alone, and rats given both drugs regained less weight after stopping treatment. Researchers caution this weight regain benefit has only been shown in animals and still needs confirmation in people before any conclusions about preventing rebound weight gain after GLP-1 therapy can be drawn.

This article is for education only. It is not medical advice. Compounds discussed here are sold for research purposes. Talk to a licensed clinician before making health decisions.